---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-23-000032"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:51:48.276447+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Labcorp appoints Brian Caveney as President Early Development & Chief Medical Officer amid spin-off prep

## Summary
- Brian J. Caveney appointed Executive Vice President, President Early Development & Chief Medical and Scientific Officer effective May 1, 2023.
- His base salary increased to $650,000 as part of the organizational restructuring for the planned spin-off.
- He will receive RSU and performance share awards each valued at $67,000, plus a stock option award valued at $201,000 on May 5, 2023.

## SEC filing metadata
- accession: 0000920148-23-000032
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014823000032/0000920148-23-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014823000032/lh-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-23-000032
- JSON: https://secwatch.observer/filing/0000920148-23-000032.json
- Plain text: https://secwatch.observer/filing/0000920148-23-000032.txt

## Key facts
- Executive change
  Brian J. Caveney was appointed as Executive Vice President, President Early Development & Chief Medical and Scientific Officer at LABCORP HOLDINGS INC..
  - Action: appointed
  - Role: Executive Vice President, President Early Development & Chief Medical and Scientific Officer
  source text: Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000032/0000920148-23-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.